Article Information
PubMed
Print ISSN
Online ISSN
History
- Received January 29, 2008
- Accepted March 5, 2008
- Published online May 19, 2008.
Article Versions
- Earlier version (March 10, 2008 - 08:00).
- You are viewing the most recent version of this article.
Copyright & Usage
The American Society for Pharmacology and Experimental Therapeutics
Author Information
- Ken-ichi Umehara,
- Megumi Iwai,
- Yasuhisa Adachi,
- Takafumi Iwatsubo,
- Takashi Usui and
- Hidetaka Kamimura
- Drug Metabolism Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., Tokyo, Japan (K.U., M.I., T.I., T.U., H.K.); and ADME/TOX Research Institute, Sekisui Medical Co., Ltd., Ibaraki, Japan (Y.A.)
- Address correspondence to:
Ken-ichi Umehara, Drug Metabolism Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., 1-8, Azusawa 1-chome, Itabashi-ku, Tokyo 174-8511, Japan. E-mail: kenichi.umehara{at}jp.astellas.com
Statistics from Altmetric.com
Article usage
In this issue
Hepatic Uptake and Excretion of (–)-N-{2-[(R)-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a Novel If Channel Inhibitor, in Rats and Humans
